Naloxone nasal spray - Adapt Pharma/Opiant Pharmaceuticals

Drug Profile

Naloxone nasal spray - Adapt Pharma/Opiant Pharmaceuticals

Alternative Names: LT-12; LT-20; LT-21; LT-22; Naloxon B; NARCAN Nasal Spray; Narcan Nasal Spray

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator Lightlake Therapeutics
  • Developer Adapt Pharma; National Institute on Drug Abuse; Opiant Pharmaceuticals; University of Pennsylvania
  • Class Antidotes; Morphinans; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Eating disorders

Highest Development Phases

  • Marketed Opioid abuse
  • Phase II Cocaine abuse; Eating disorders
  • Phase I Bulimia nervosa; Drug abuse

Most Recent Events

  • 25 Jan 2017 Registered for Opioid abuse in USA (Intranasal, 2mg)
  • 15 Dec 2016 Opiant Pharmaceuticals signs agreement with SWK Holdings Corporation for naloxone nasal spray royalty monetisation
  • 15 Dec 2016 Launched for Opioid abuse in Canada (Intranasal) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top